JANUARY 14
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil

Platform
Technology

  1. mRNA/Nanoparticle
  2. Protein Engineering
  • mRNA/Nanoparticle

    MOGAM has exceptional history of experience specializing in developing protein-based therapeutics, such as PEGylated G-CSF, coagulation factors, and monoclonal antibodies. Moving towards the next generation of therapeutics, we are now focusing on mRNA-based therapeutics. Based on our existing competencies, we have been researching mRNA components and nanoparticles (NPs) and increasing our competitiveness through open innovation.

    mRNA encapsulated LNP
    Cellular uptake mechanism
    • 1. Once nanoparticles are administered to the body, the
      nanoparticles then enter the membrane of the target cell of interest through endocytosis.
    • 2. By forming endosomes, nanoparticles are internalized into the cells.
    • 3. Developed into late endosomes, the acidic environment
      within these endosomes leads the pH-dependent ionizable lipids to create disruptions and release the payload (mRNA) in the nanoparticle, which is then followed by the biodegradation of the nanoparticle components.
    • 4. Together with translation machinery in the cytosol, the released mRNA is decoded to produce functional proteins.
  • Protein Engineering
    Antibody
    Library

    An antibody library is an essential and important platform in the field of discovery of antibody therapeutics. MOGAM has generated two formats of antibody libraries with Fab and heavy chain variable domains (VH). The human-like synthetic Fab library constructed by combining the high throughput sequencing (HT-sequencing) information about the human variable gene repertoire, and a novel approach to design synthetic codons. We confirmed that the design of CDRs was precisely embodied in the library with an expected quality by HT sequencing. The VH domain library was constructed using rationally controlled CDRs to overcome the lack of binding sites and further engineered to have high levels of thermodynamic stability, soluble expression, and reversible folding.

    Screening
    Systems
    1) Antibody screening system

    Antibodies can be effectively generated through a B cell library using human and mouse immune responses and a synthetic library of various antibody formats.

    2) Protein Engineering & Screening system In silico modeling

    - Using structure analysis software to perform structure modeling and simulation docking, etc.

    - Library design to improve protein efficacy based on the analyzed data

    Protein
    Engineering
    1) Hyper-stable single domain antibody

    MOGAM developed hyper-stable VH domain antibody similar to the igG level using own protein engineering & screening system

    2) Multi-specific antibody technology

    Easy to multimerization for binding various targets

    We are Open
    to Collaborate
    Using This Platform!